Table 3.
Characteristics of Participants who withdrew consent from the study
| Reason for withdrawal | Duration of treatment (month) | Baseline/last albumin (g/dL) | Baseline/last alpha-1 antitrypsin (mg/dL) | Withdrawal type | Additional notes | |
|---|---|---|---|---|---|---|
| Patient 1 | Mild abdominal discomfort, did not feel improvement with treatment | 1 | 3.9/2.4 | 444.26/NA | Voluntary | No significant adverse effects noted |
| Patient 2 | Mild abdominal discomfort, did not feel improvement with treatment | 1 | 2.0/2.1 | 383.32/49.1 | Voluntary | No significant adverse effects noted |
| Patient 3 | Diarrhea (PLE symptom) persisted despite treatment | 3 | 2.2/1.5 | 313.1/294.3 | Voluntary |
No significant adverse effects noted Symptoms related to PLE exacerbation |
| Patient 4 | Diarrhea (PLE symptom) persisted despite treatment | 3 | 2.8/3.0 | 185.6/338.9 | Voluntary |
No significant adverse effects noted Symptoms related to PLE exacerbation |